New strategies in plastic surgery: autologous adipose-derived mesenchymal stem cells contained in fat grafting improves symptomatic scars

Gentile, Pietro

doi:10.52586/4940

Cited by 20 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have found that the stromal vascular fraction (SVF) and decellularized extracellular matrices (ECM) may act as enhanced therapeutic medicinal products [ 10 ]. MSCs, biomaterials and platelet-rich plasma are novel regenerative approaches that can be used in chronic skin wounds as well as soft tissue defects [ 11 , 12 ]. More and more investigations confirmed that exosomes (Exos) of MSCs have indispensable roles to regulate angiogenesis-based wound healing [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Exosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery

Tang,

Chen,

Zhang

et al. 2024

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Exosomes (Exos) generated from bone mesenchymal stem cells (BMSCs) are elucidated to enhance cutaneous wound healing in mice models of diabetes mellitus (DM). While underlying mechanisms remain unknown. Methods Next-generation sequencing (NGS) was used to examine changes in circRNA expression levels following Exo treatment. Luciferase assays were used to determine the interactions between RNAs. Immunofluorescence staining was used to examine reactive oxygen species (ROS) in endothelial progenitor cells (EPCs) cultured in high glucose (HG) conditions. Therapeutic effects regarding Exos were also examined by immunofluorescence. Results We found that Exo treatment enhanced cutaneous wound healing significantly. NGS indicated that circ-Snhg11 was involved in Exo-mediated tissue repairing. Downregulation of circ-Snhg11 decreased Exo-mediated therapy responses during wound healing in diabetic mouse. Our luciferase reporter data confirmed that SLC7A11 and miR-144-3p were circ-Snhg11 downstream targets. miR-144-3p overexpression or SLC7A11 knockdown altered the protective effects of circ-Snhg11 upon EPCs exposed to HG conditions. Upregulation of circ-Snhg11 incremented therapy effects of Exo treatment during wound healing in DM mice through enhanced angiogenesis along with a reduction in GPX4-mediated ferroptosis. Conclusions circ-Snhg11 in BMSC-Exos enhanced SLC7A11/GPX4-mediated anti-ferroptosis signals via miR-144-3p sponging resulting in enhanced diabetic wound healing and improved angiopoiesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Exosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery

Tang,

Chen,

Zhang

et al. 2024

Diabetol Metab Syndr

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that this method is effective for managing scars in a large number of patients. 22 , 23 Previous studies show that the application of SVF can promote tissue healing and maintain the volume of fat transplantation. Li M et al.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of stromal vascular fraction in the treatment of scars: A systematic review and meta‐analysis

Qiu,

Gan,

Chen

2024

Skin Research and Technology

View full text Add to dashboard Cite

ObjectiveOur aim was to assess the effectiveness of stromal vascular fraction (SVF) in treating scars using the latest meta‐analysis.MethodsWe used PubMed, Embase, Cochrane, and Web of Science to search the studies used to evaluate the efficacy of SVF in scar treatment. At least one of the following outcome measures were reported: vascularity, pigmentation, thickness, relief, pliability, surface area, pain, itching and color.ResultsA total of four eligible articles comprising 145 patients (64 SVF patients and 81 non‐SVF patients) were included. The findings of this meta‐analysis indicated that SVF had significant therapeutic effects in terms of vascularity (SMD/MD, 95% CI: ‐1.12, ‐0.02; p = 0.04), itching (SMD/MD, 95% CI: ‐0.61, ‐0.13; p = 0.002), POSAS (SMD/MD, 95% CI: ‐5.93, ‐1.47; p = 0.001), and thickness (SMD/MD, 95% CI: ‐1.04, ‐0.35; p < 0.001). In terms of OSAS (SMD/MD, 95% CI: ‐9.14, 0.59; p = 0.09), pigmentation (SMD/MD, 95% CI: ‐1.02, 0.06; p = 0.08), relief (SMD/MD, 95% CI: ‐1.14, 0.16; p = 0.14), surface area (SMD/MD, 95% CI: ‐0.91, 0.26; p = 0.27), PSAS (SMD/MD, 95% CI: ‐7.20, 0.49; p = 0.09), pain (SMD/MD, 95% CI: ‐0.87, 0.07; p = 0.10), pliability (SMD/MD, 95% CI: ‐0.57, 0.01; p = 0.06), and color (SMD/MD, 95% CI: ‐1.78, 0.48; p = 0.26), there were no significant statistical differences.ConclusionIn view of the heterogeneity and potential selective bias, further large‐scale, prospective, and multicenter clinical trials are needed to confirm the efficacy and reliability of SVF in the treatment of scars.

show abstract

“…Taking adipose tissue-derived MSCs (AD-MSCs) as one of the most accessible and important sources of MSCs, they are currently primarily used in the following areas: (1) Plastic and esthetic surgery: AD-MSCs are widely utilized in plastic and esthetic surgeries. They can be used for tissue filling and repair, such as treating facial wrinkles, skin scars [ 12 – 14 ], and breast reconstruction [ 15 – 17 ]. (2) Arthritis and cartilage injury treatment: AD-MSCs have demonstrated potential effects in the treatment of arthritis and cartilage injuries.…”

Section: Introductionmentioning

confidence: 99%

The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy

Li,

Wu,

Zhao

et al. 2023

Stem Cell Res Ther

View full text Add to dashboard Cite

With the continuous improvement of human technology, the medical field has gradually moved from molecular therapy to cellular therapy. As a safe and effective therapeutic tool, cell therapy has successfully created a research boom in the modern medical field. Mesenchymal stem cells (MSCs) are derived from early mesoderm and have high self-renewal and multidirectional differentiation ability, and have become one of the important cores of cell therapy research by virtue of their immunomodulatory and tissue repair capabilities. In recent years, the application of MSCs in various diseases has received widespread attention, but there are still various problems in the treatment of MSCs, among which the heterogeneity of MSCs may be one of the causes of the problem. In this paper, we review the correlation of MSCs heterogeneity to provide a basis for further reduction of MSCs heterogeneity and standardization of MSCs and hope to provide a reference for cell therapy.

show abstract

New strategies in plastic surgery: autologous adipose-derived mesenchymal stem cells contained in fat grafting improves symptomatic scars

Abstract: No abstract present.

Cited by 20 publications

References 24 publications

Exosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery

Exosomes derived from BMSCs enhance diabetic wound healing through circ-Snhg11 delivery

Efficacy of stromal vascular fraction in the treatment of scars: A systematic review and meta‐analysis

The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy

Contact Info

Product

Resources

About